MicroRNAs as biomarkers of environmental and occupational exposure to asbestos;I microRNA come indicatori biologici di esposizione ambientale e occupazionale ad amianto

Giornale Italiano di Medicina del Lavoro ed Ergonomia

Volumn 33, Issue 4, 2011, Pages 420-434

  Minoia, Claudio ^a,c   Sturchio, Elena ^b   Porro, Benedetta ^a   Ficociello, Barbara ^b   Zambelli, Alberto ^a   Imbriani, Marcello ^c  

^a IRCCS   (Italy)

^b ISPESL   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Asbestos exposure; Diagnostic biomarkers and prognostic factors; Genetic polymorphisms; Mesothelioma; MicroRNAs

Indexed keywords

ASBESTOS; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MESOTHELIN; MICRORNA; OSTEOPONTIN;

ARTICLE; ENVIRONMENTAL EXPOSURE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HUMAN; MESOTHELIOMA; OCCUPATIONAL EXPOSURE; PERITONEUM TUMOR; PLEURA TUMOR; PROGNOSIS;

ASBESTOS; ENVIRONMENTAL EXPOSURE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GPI-LINKED PROTEINS; HUMANS; MESOTHELIOMA; MICRORNAS; OCCUPATIONAL EXPOSURE; OSTEOPONTIN; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; PROGNOSIS;

EID: 84857857001     PISSN: 15927830     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (141)

1. Addis B, Roche H. Problems in mesothelioma diagnosis. Histo- pathology 2009; 54: 55-68.
2. Amatori S, Papalini F, Lazzarini R, Donati B, Bagaloni I, Rippo MR, Procopio A, Pelicci PG, Catalano A, Fanelli M. Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. Lung Cancer 2009; 66: 184-190.
3. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, Rosenberg A. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009; 219: 214-221.
4. Balatti V, Maniero S, Ferracin M, Veronese A, Negrini M, Ferrocci G, Martini F, Tognon MG. MicroRNAs Dysregulation in Human Malignant Pleural Mesothelioma. J Thorac Oncol 2011.
5. Balsara BR, Bell DW, Sonoda G, De Rienzo A, du Manoir S, Jhanwar SC, Testa JR. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15ql 1.1-15 in human malignant mesothelioma. Cancer Res 1999; 59: 450-454. (Pubitemid 29048882)
6. Bell DW, Jhanwar SC, Testa JR. Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. Cancer Res 1997, 57: 4057-4062. (Pubitemid 27427697)
7. Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, Ashkenazi K, Goren E, Meiri E, Morgenstern S, Perelman M, Barshack I, Goren Y, Edmonston TB, Chajut A, Aharonov R, Bentwich Z, Rosenfeld N, Cohen D. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn 2010; 12: 771-779.
8. Betti M, Neri M, Ferrante D, Landi S, Biava A, Gemignani F, Bertolotti M, Mirabelli D, Padoan M, Ugolini D, Botta M. Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma. Int J Hyg Environ Health 2009; 212: 322-329.
9. Betti M, Ferrante D, Padoan M, Guarrera S, Giordano M, Aspesi A, Mirabelli D, Casadio C, Ardissone F, Ruffini E, Betta PG, Libener R, Guaschino R, Matullo G, Piccolini E, Magnani C, Dianzani I. XRCC1 and ERCC1 variants modify malignant mesothelioma risk: A case-control study. Mutation Research 2011; 708: 11-20.
10. Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Sei- zinger B, Kley N, Klein-Szanto AJ, Testa JR. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995; 92: 10854-10858.
11. Bjorkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S. Recurrent DNA copy number changes in Iq, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 1997; 75: 523-527. (Pubitemid 27085293)
12. Bocchetta M, Eliasz S, De Marco MA, et al. The SV40 large T anti- gen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res 2008; 68: 1022-1029. (Pubitemid 351272219)
13. Bonfrer JM, Schouwink JH, Korse CM, Baas P. Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res 1997; 17: 2971-2973. (Pubitemid 27434834)
14. Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, Gaudino G. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 2010; 42: 312-319.
15. Cacciotti P, Libener R, Betta P, et al. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 2001; 98: 12032-12037. (Pubitemid 32959821)
16. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio M V, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzón R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801. (Pubitemid 41549891)
17. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down- regulation of micro-RNA genes miR 15 and miR 16 at 13q 14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529. (Pubitemid 35403967)
18. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004. (Pubitemid 38327724)
19. Cao CQ, Munkholm-Larsen S, Yan TD. Malignant peritoneal mesothelioma. World J Gastro Surg 2009; 1: 38-48.
20. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelioma, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996; 93: 136-140. (Pubitemid 26041483)
21. Chen Q, Marsh J, Ames B, Mossman B. Detection of 8-oxo-2'- deoxyguanosine, a marker of oxidative DNA damage, in culture medium from human mesothelial cells exposed to crocidolite asbestos. Carcinogenesis 1996; 17: 2525-2527. (Pubitemid 26402257)
22. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
23. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR. pl6 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54: 5547-5551.
24. Cheng JQ, Lee WC, Klein MA, Cheng GZ, Jhanwar SC, Testa JR. Frequent mutations of NF2 and allelic loss from chromosome band 22q 12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 1999; 24: 238-42. (Pubitemid 29070163)
25. Christensen BC, Godleski JJ, Marsit CJ., et al. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis 2008; 29: 1555-1559.
26. Christensen BC, Godleski JJ, Roelofs CR, Longacker JL, Bueno R, Sugarbaker DJ, Marsit CJ, Nelson HH, Kelsey KT. Asbestos burden predicts survival in pleural mesothelioma. Environ Health Perspect 2008; 116: 723-726. (Pubitemid 351943926)
27. Christensen BC, Houseman EA, Godleski JJ, Marsit CJ, Longacker JL, Roelofs CR, Karagas MR, Wrensch MR, Yeh R, Nelson HH, Wiemels JL, Zheng S, Wiencke JK, Bueno R, Sugarbaker DJ and Kelsey KT. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res 2009; 69: 227-234.
28. Chuang JC, Jones PA. Epigenetics and microRNAs. Ped Res 2007; 61: 24R-29R. (Pubitemid 46653064)
29. Cole GW, Alleva AM, Zuo JT, Sehgal SS, Yeow WS, Schrump DS, Nguyen DM. Suppression of prometastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor U0126. Anticancer Res 2006; 26: 809-821.
30. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007, 13: 5076-5081. (Pubitemid 47502073)
31. Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Bruno R, Landi D, Gemignani F, Landi S. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. Occup Environ Med 2010; 67: 233-236.
32. De Rienzo A, Jhanwar SC, Testa JR. Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. Genes Chromosomes Cancer 2000; 28: 337-341. (Pubitemid 30399564)
33. Dianzani I, Gibello L, Biava A, Giordano M, Bertolotti M, Betti M, Ferrante D, Guarrera S, Betta GP, Mirabelli D, Matullo G, Magnani C. Polymorphisms in DNA repair genes as risk factors for asbestos- related malignant mesothelioma in a general population study. Mutat Res 2006, 599: 124-134. (Pubitemid 44041510)
34. Dodson RF, Williams MG, Corn CJ, Brollo A, Bianchi C. Asbestos content of lung tissue, lymph nodes, and pleural plaques from former shipyard workers. Am Rev Respir Dis 1990; 142: 843-847. (Pubitemid 20344655)
35. Dodson RF, O'Sullivan MF, Huang J, Holiday DB, Hammar SP. Asbestos in extrapulmonary sites - omentum and mesentery. Chest 2000; 117:486-493. (Pubitemid 30111603)
36. Esquela-Kercher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-69.
37. Fabbri M, Ivan M, Cimmino A, Negrini M, Calin GA. Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther 2007; 7: 1009-1019.
38. Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M, Swanson SJ, Godfrey TE, Litle VR. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008; 135: 255-260.
39. Fleury-Feith J, Lecomte C, Renier A, et al. Hemizygosity of Nf2 is associated with increased susceptibility to asbestos induced peritoneal tumours. Oncogene 2003; 22: 3799-3805. (Pubitemid 36760742)
40. Forootan SS, Foster CS, Aachi VR, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006; 118: 2255-2261.
41. Franko A, Dodic-Fikfak M, Amené N, Dolzan V. Manganese and Extracellular Superoxide Dismutase Polymorphisms and Risk for Asbestosis. J Biomed Biotechnol 2009; 2009: 493083. doi:l 0.1155/2009/493083.
42. Galffy G, Mohammed KA, Dowling PA, et al. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 1999; 59: 367-371. (Pubitemid 29048869)
43. Gee GV, Koestler DC, Christensen BC, Sugarbaker DJ, Ugolini D, Ivaldi GP, Resnick MB, Houseman EA, Kelsey KT and Marsit CJ. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer 2010; 127: 2859-2869.
44. Gemignani F, Neri M, Bottari F, Barale R, Canessa PA, Canzian F, Ceppi M, Spitaleri I, Cipollini M, Ivaldi GP, Mencoboni M, Scaruffi P, Tonini GP, Ugolini D, Mutti L, Bonassi S, Landi S. Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism. Mutation Research 2009; 671: 76-83.
45. Gotoh M, Sakamoto M, Kanetaka K, et al. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002; 52: 19-24. (Pubitemid 34299209)
46. Graziani I, Eliasz S, De Marco MA, Chen Y, Pass HI, De May RM, Strack PR, Miele L, Bocchetta M. Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway. Cancer Res 2008; 68: 9678-9685.
47. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601. (Pubitemid 351627379)
48. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007; 13: 2928-2935. (Pubitemid 46850705)
49. Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, Knuutila S. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma - A miRNA microarray analysis. Genes, Chromosomes & Cancer 2009; 48: 615-623.
50. Hansen K, Mossman B. Generation of superoxide from alveolar macrophages exposed to asbestiform and nonfibrous particles. Cancer Res 1987; 47: 1681-1686. (Pubitemid 17044503)
51. Haque AK, Vrazel DM, Burau KD. Is there transplacental transfer of asbestos? A study of 40 stillborn infants. Pediatr Pathol 1996; 877-892. (Pubitemid 26394007)
52. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M. Detection and quantitation of serum mesothelin, a tumor marker for patient with mesothelioma and ovarian cancer. Clin Cancer Research 2006; 12: 447-453. (Pubitemid 43166134)
53. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006; 27: 1086-1095. (Pubitemid 44914290)
54. Henderson JP, Byun J, Takeshita J, Heinecke JW. Phagocytes produce 5-chlorouracil and 5-bromouracil, two mutagenic products of myeloperoxidase, in human inflammatory tissue. The Journal of biological chemistry 2003; 278: 23522-23528. (Pubitemid 36830171)
55. Henzi T, Blum WV, Pfefferli M, Kawecki TJ, Salicio V, Schwaller B. SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis. Am J Pathol 2009; 174: 2324-2336.
56. Hirao T, Bueno R, Chen C, Gordon GJ, Heilig E and Kelsey KT. Alterations of the pl6INK4 locus in human malignant mesothelial tumors. Carcinogenesis 2002; 23: 1127-1130. (Pubitemid 34814769)
57. Hirvonen A, Pelin K, Tammilehto L, Karjalainen A, Mattson K, Linnainmaa K. Inherited GSTM1, NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res 1995; 55: 2981-2983.
58. Hirvonen A, Saarikoski ST, Linnainmaa K, Koskinen K, Husgafvel- Pursiainen K, Mattson K, Vainio H. Glutathione S-transferase and Nacetyltransferase genotypes and asbestos-associated pulmonary disorders. J Natl Cancer Inst 1996; 88: 1853-1856. (Pubitemid 26425061)
59. Hirvonen A, Tuimala J, Olhkainen T, Linnainmaa K, Kinnula V. Manganese superoxide dismutase genotypes and asbestos-associated pulmonary disorders. Cancer Letters 2002; 178: 71-74. (Pubitemid 34159243)
60. Husain AN, Colby TV, Ordoñez NG, Krausz T, Borczuk A. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma Arch Pathol Lab Med 2009; 133: 1317-1331.
61. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006; 94: 776-780.
62. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070. (Pubitemid 41161233)
63. Ivanov SV, Miller J, Lucito R, Tang C, Ivanova AV, Pei J, Carbone M, Cruz C, Beck A, Webb C, Nonaka D, Testa JR, Pass HI. Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer 2008; 124: 589-599.
64. Ivanov SV, Goparaju CM, Lopez P, Zavadil J, Toren-Haritan G, Ro- senwald S, Hoshen M, Chajut A, Cohen D, Pass HI. Pro-tumorige- nic effects of miR-31 loss in mesothelioma. J Biol Chem 2010; 285: 22809-22817.
65. Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao A, Wi- stuba I, Roth J, Pass HI. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Molecular Cancer 2009, 8:91.
66. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL, Salgia R. Functional analysis of c- Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006; 66: 352-361. (Pubitemid 43166042)
67. Jaurand MC. Mechanisms of fiber-induced genotoxicity. Environmental health perspectives 1997; 105: 1073-1084.
68. Kelsey KT, Yano E, Liber HL, Little JB. The in vitro genetic effects of fibrous erionite and crocidolite asbestos. British journal of cancer 1986; 54: 107-114. (Pubitemid 16093191)
69. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-1679. (Pubitemid 34289219)
70. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010; 50: 298-301.
71. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39: 673-677. (Pubitemid 46676103)
72. Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marineóla FM, Tucker MA, Bertazzi PA, Pesatori AC, Caporaso NE, McShane LM, Wang E. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010; 16: 430-441.
73. Landi S, Gemignani F, Neri M, Barale R, Bonassi S, Bottari F, Canessa PA, Canzian F, Ceppi M, Filiberti R, Ivaldi GP, Mencoboni M, Scaruffi P, Tonini GP, Mutti L, Puntoni R. Polymorphisms of glutathione-S-transferase Ml and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. Int J Cancer 2007; 120: 2739-2743. (Pubitemid 46651299)
74. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-675. (Pubitemid 351667616)
75. Lee WC, Balsara B, Liu Z, Suresh C, Jhanwar S, Testa JR. Loss of heterozygosity analysis defines a critical region in chromosome lp22 commonly deleted in human malignant mesothelioma. Cancer Res 1996; 56: 4297-4301. (Pubitemid 26330424)
76. Lee Y S, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009; 4: 199-227.
77. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20. (Pubitemid 40094598)
78. Lindholm PM, Salmenkivi K, Vauhkonen H, Nicholson AG, Anttila S, Kinnula VL, Knuutila S. Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH. Cytogenet Genome Res 2007; 119: 46-52.
79. Lippman M. Effects of fiber characteristics on lung deposition, retention, and disease. Environ Health Perspect 1990; 88: 311-317.
80. London SJ, Daly AK, Cooper J, Navidi WC, Carpenter CL, Idle JR. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. J Natl Cancer Inst 1995; 87: 1246-1253.
81. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838. (Pubitemid 40839735)
82. Lu YY, Suresh C, Jhanwar S, Cheng JQ, Testa JR. Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosomes Cancer 1994; 49: 76-80. (Pubitemid 24007501)
83. Lujambio A, Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 2007; 6: 1455-1459.
84. Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther 2010; 17: 523-531.
85. Makunin IV, Pheasant M, Simons C, Mattick JS. Orthologous microRNA genes are located in cancer-associated genomic regions in human and mouse. PLoS ONE 2007; 2: el 133.
86. Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature 2005; 435: 745-746. (Pubitemid 40839710)
87. Mendell JT. Miriad roles for the miR-17-92 cluster in development and disease. Cell 2008; 133: 217-222. (Pubitemid 351508308)
88. Metheny-Barlow LJ, Flynn B, van Gijssel HE, Marrogi A, Gerwin BI. Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo. Am J Respir Cell Mol Biol 2001; 24: 694-702. (Pubitemid 32550591)
89. Michael MZ, O'Connor SM, van Hoist Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1: 882-891. (Pubitemid 37288707)
90. Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 1999; 180: 150-157. (Pubitemid 29297191)
91. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008; 14: 2690-2695.
92. Neri M, Filiberti R, Taioli E, Garte S, Paracchini V, Bolognesi, C, Canessa, PA, Fontana V, Ivaldi GP, Verna A, Bonassi S, Puntoni R. Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure. Mutat Res 2005; 592: 36-44. (Pubitemid 41714042)
93. Neri M, Taioli E, Filiberti R, Ivaldi GP, Canessa PA, Verna A, Marroni P, Puntoni R, Hirvonen A, Garte S. Metabolic genotypes as modulators of asbestos-related pleural malignant mesothelioma risk: a comparison of Finish and Italian populations. Int J Hyg Environ Health 2006; 209: 393-398. (Pubitemid 43929421)
94. Neri M, Ugolini D, Dianzani I, Gemignani F, Landi S, Cesario A, Magnani C, Mutti L, Puntoni R, Bonassi S. Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases Mutation Research 2008; 659: 126-136.
95. Paganuzzi M, Onetto M, Marroni P, Filiberti R, Tassara E, Parodi S, Felletti R. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 2001; 119: 1138-1142. (Pubitemid 32679442)
96. Park E, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS and Johnson AR. Soluble Mesothelin-Related Protein in an asbestosexposed population. Am J Respir Crit Care Med 2008; 178:832-837.
97. Pass HI, Bocchetta M, Carbone M. Evidence of an important role for SV40 in mesothelioma Thorac Surg Clin 2004; 14: 489-495. (Pubitemid 39314482)
98. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, et al. Soluble mesothelin-related peptide level elevation in Mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85: 265-272. (Pubitemid 350265805)
99. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 1564-1573. (Pubitemid 41434635)
100. Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, Benjamin S, Aharonov R. Hsa-Mir-29c is Linked to the Prognosis of Malignant Pleural Mesothelioma. Cancer Res 2010; 70: 1916-1924.
101. Pietruska JR, Johnston T, Zhitkovich A, Kane AB. XRCC1 deficiency sensitizes human lung epithelial cells to genotoxicity by crocidolite asbestos and libby amphibole. Environmental Health Perspectives 2010; 118: 1707-1713.
102. Prometheus Laboratories Inc. ProOnc MesotheliomaDX: Prometheus Therapeutics & Diagnostics. San Diego, CA: Prometheus Laboratories Inc., 2009.
103. Ramos-Nino ME, Timblin CR, Mossman BT. Mesothelial cell transformation requires increased AP-1 binding activity and ERK- dependent Fra-1 expression. Cancer Res 2002; 62: 6065-6069. (Pubitemid 35244454)
104. Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, Mossman BT. Cellular and molecular parameters of mesothelioma. J Cell Biochem 2006; 98: 723-734. (Pubitemid 43993391)
105. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2010. doi.l0.1016/j.critrevonc.2010.1i.004.
106. Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, Klerk ND, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616. (Pubitemid 37443528)
107. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, Lebanony D, Goren Y, Silberschein E, Targan N, Ben-Ari A, Gilad S, Sion-Vardy N, Tobar A, Feinmesser M, Kharenko O, Nativ O, Nass D, Perelman M, Yosepovich A, Shalmon B, Polak-Charcon S, Fridman E, Avniel A, Bentwich I, Bentwich Z, Cohen D, Chajut A, Barshack I. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008; 26: 462-469. (Pubitemid 351501813)
108. Rosenwald S, Gilad S, Benjamin S, et al. Validation of a microRNA- based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol 2010; 23:814-823.
109. Salama G, Miédougé M, Rouzaud P, Mauduyt MA, Pujazon, MC, Vincent C, Carles P, Serre, G. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br J Cancer 1998; 77: 472-476. (Pubitemid 28044054)
110. Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D, Pozzi V, Carbonari D, Bracci M, Pignotti E, Mazzanti P, Sabbatini A, Ranaldi R, Gasparini S, Neuzil J, Tomasetti M. Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma. PLoS One 2011; 6: e 18232.
111. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006, 173: 1155-1160. (Pubitemid 43726897)
112. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, Minna JD. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995; 55: 1227-1231.
113. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, Minna JD. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995; 55: 1227-1231.
114. Sharp JA, Sung V, Slavin J, et al. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab Invest 1999; 79: 869-877. (Pubitemid 29344499)
115. Shiomi K, Shiomi S, Ishinaga Y, Sakuraba M, Hagiwara Y, Miyashita K, Maeda M, Suzuki K, Takahashi K, Hino O. Impact of renal failure on the tumor markers of mesothelioma, N- ERC/mesothelin and osteopontin. Anticancer Res 2011; 31:1427- 1430.
116. Park EK, Thomas PS, Johnson AR, Yates DH. Osteopontin levels in an asbestos-exposed population. Clin Cancer Res 2009; 15: 1362-1366.
117. Shivapurkar N, Virmani AK, Wistuba II, Milchgrub S, Mackay B, Minna JD, Gazdar AF. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res 1999; 5: 17-23. (Pubitemid 29045173)
118. Simpson RJ, Jensen SS, Lim JW. Proteomic profiling of exosomes: current perspectives. Proteomics 2008; 8: 4083-4099.
119. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001; 193: 468-475. (Pubitemid 32266815)
120. Stucker I, Boffetta P, Antilla S, Benhamou S, Hirvonen A, London S, Taioli E. Lack of interaction between asbestos exposure and glutathione S-transferase M1 and T1 genotypes in lung carcinogenesis. Cancer Epidemiol Biomarkers Prev 2001; 10: 1253-1258. (Pubitemid 34027756)
121. Sutton A, Imbert A, Igoudjil A, Descatoire V, Cazanave S, Pessayre D, Degoul F. The manganese superoxide dismutase AlaI6Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 2005; 15: 311-319. (Pubitemid 40676552)
122. Suzuki Y, Yuen SR, Ashley R. Short, thin asbestos fibers contribute to the development of human malignant mesothelioma: pathological evidence. Int J Hyg Environ Health 2005; 208: 201-210. (Pubitemid 40592093)
123. Suzuki M, Toyooka S, Shivapurkar N, Shigematsu H, Miyajima K, Takahashi T, Stastny V, Zem AL, Fujisawa T, Pass HI, Carbone M and Gazdar AF: Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogene 2005; 24: 1302-1308. (Pubitemid 40313933)
124. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, En- doh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-3756. (Pubitemid 38697282)
125. Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K, Ueda Y, Mitsudomi T, Horio Y, Hida T, Yatabe Y, Seto M, Sekido Y. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on lp32. Cancer Sci 2007; 98: 438-446. (Pubitemid 46195618)
126. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2009; 64: 140-147.
127. Tomatis L, Cantoni S, Carnevale F, Merler E, Mollo F, Ricci P, Silvestri S, Vineis P, Terracini B. The Role of Asbestos Fiber Dimensions in the Prevention of Mesothelioma Int J Occup Environ Health 2007; 13: 64-69.
128. Tsou JA, Shen LY, Siegmund KD, Long TI, Laird PW, Seneviratne CK, Koss MN, Pass HI, Hagen JA, Laird-Offringa IA. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer 2005; 47: 193-204. (Pubitemid 40082162)
129. Tsou JA, Galler JS, Wali A, Ye W, Siegmund KD, Groshen S, Laird PW, Turla S, Koss MN, Pass HI, Laird-Offringa IA. DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer 2007; 58: 220-230. (Pubitemid 47513257)
130. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998; 79: 127-132. (Pubitemid 28201682)
131. Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic acids research 2004; 32: 4100-4108. (Pubitemid 39232282)
132. Villanova F, Procopio A, Rippo MR. Malignant mesothelioma resistance to apoptosis: recent discoveries and their implication for effective therapeutic strategies. Curr Med Chem 2008; 15: 631-641. (Pubitemid 351516800)
133. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261. (Pubitemid 43271657)
134. Wang LI, Neuberg D, Christiani DC. Asbestos exposure, manganese superoxide dismutase (MnSOD) genotype, and lung cancer risk. Journal of Occupational and Environmental Medicine 2004; 46: 556-564. (Pubitemid 38747701)
135. Weitzman S and Graceffa P. Asbestos catalyzes hydroxyl and superoxide radical generation from hydrogen peroxide Arch. Biochem. Biophys 1984; 228: 373-376. (Pubitemid 14175786)
136. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of and pi6 in primary malignant mesothelioma. Oncogene 1995; 11:511-515.
137. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-198. (Pubitemid 43357945)
138. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, Bubici C, Mossman BT, Pass HI, Testa JR, Franzoso G, Carbone M. TNF-inhibits asbestos induced cytotoxicity via a NF-I B-depen- dent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 2006; 103: 10397-10402. (Pubitemid 44051178)
139. Zhang J, Takahashi K, Takahashi F, et al. Differential osteopontin expression in lung cancer. Cancer Lett 2001; 171: 215-222. (Pubitemid 32772809)
140. Zhao XH, Jia G, Liu YQ, Liu SW, Yan L, Jin Y, Liu N. Association between polymorphisms of DNA repair gene XRCC1 and DNA damage in asbestos-exposed workers. Biomed Environ Sci 2006, 19: 232-238.
141. Zhong W, Oberley LW, Oberley TD, Yan T, Domann FE, St. Clair DK. Inhibition of cell growth and sensitization to oxidative damage by overexpression of manganese superoxide dismutase in rat glioma cells. Cell Growth and Differentiation 1996; 7: 1175-1186. (Pubitemid 26360698)